- Details
- Written by Super User
- Category: Info
Organizing committee
ALTABEF Muriel – Associate Director - Multi-Organization Thematic Institute Cancer of Aviesan
BILLACOIS Myriam – Communication Officer - Inserm
BONNEVILLE Marc – CEO of ARIIS and Scientific & Medical Director – Institut Mérieux
CHOMIENNE Christine – Director - Multi-Organization Thematic Institute Cancer of Aviesan
COSTE Hervé – Expertise & Sourcing Director – Inserm Transfert
D’ASTIER Catherine – Communication Associate Director - Inserm
DEFAUX Aurélie – Project Leader - ARIIS
FIORINI Marco – Secretary general - ARIIS
FOUINAT Véronique – Management Assistant – ARIIS
KEREMIAN Diana – Management Assistant - Multi-Organization Thematic Institute Cancer of Aviesan
MORILLON Estelle - Scientific Project Manager - Inserm Transfert
SENDEYO Kehlia – Project Leader - Therapeutic innovation in the field of cancer, CVT of Aviesan
Industrials members of steering committee
BARRIERE Cédric - External Innovation For Oncology, Senior Manager - Sanofi
BEHIER Jehan-Michel – Medical Director - Takeda
BESNARD François – External Innovation Neurosciences - Sanofi
BLANC Véronique - Immuno-Oncology Program Head - Servier
BOUDIAF Lamia - Onco BU Medical Director - Novartis
BOUQUET Fanny - Project Manager Oncology – Institut Roche
BUSSOD Olivia - Strategic Alliances Manager - Pfizer
FAGES Sophie - Medical Director France - Abbvie
GAUCHER Christine - Project Leader Therapeutic Innovation - LFB
GUILBAUD Nicolas - Director of Oncology Research Partnerships - Pierre Fabre
HERVE-BANNIER Valérie – Director of institutional & economic affairs – Abbvie
KERBOUCHE Naima – Project Leader Oncology - GSK
MAHFOUDI Abderrahim - Head External Innovation Oncology - Pierre Fabre
MANSUY Lucilla - Clinical Research Unit Director - Boehringer Ingelheim
MONDON Philippe - Project Director Therapeutic Innovation - LFB
MIARA Alain – Partnerships Director - Janssen
PAROT Xavier - Medical Director Oncology - Takeda France
PERCHE Olivier - Public, Scientific and Medical Affairs Project Manager - Roche Diagnostics
QUEMENEUR Eric - Executive Vice President & Chief Scientific Officer – Transgène
SCAEROU Fréderic - Director, Scientific Affairs Oncology & Director, Scientific Intelligence - Ipsen
SHIRVANI Hamasseh - Scientist project Manager Oncology/ Immunology – Institut Roche
VAIARELLI Valérie - Regional Director - BMS
VAN HILLE Benoît – Medical Operations Manager - Merck
VAROQUEAUX Nathalie - Executive Medical Director - AstraZeneca
YAKOUBI Nawel – Scientific Partnerships Manager - MSD
- Details
- Written by Super User
- Category: Info
TeaserPublic and private partnerships are essential to foster innovation in health industries. Since the launch in 2009 of the first International R&D datings, a great number of companies committed themselves to develop private-public partnerships. Aligned with this main strategic objective, ARIIS in cooperation with the Institute of Cancer of Aviesan (the French national Alliance for life sciences and health) organizes the 8th International R&D Dating on Febuary 6th 2018 on the theme of “Immuno-oncology”.
Considered by the ASCO (American Society of Clinical Oncology) as “the clinical advance of year 2017”, the immuno-oncology has become part of the therapeutic arsenal used facing advanced cancers or recurrences. Yesterday on the prostate and the melanoma, these treatments are more and more effective against other cancers: lymphoma of Hodgkin, kidney, lung and even certain hematological cancers.
In this domain, the oldest sector of innovation concerns the targets of inhibition of control points, among which some are used in clinic. The mechanisms of signaling sent (CTLA-4 and PD-1/PD-L1, and more recently TIM3, GITR and LAG3) seem effective, even in the face of the hypermutability and the tumoral heterogeneousness. However, numerous questions remain : toxicity, stratification of patients, inhibitors' combination, addition of the other therapies, etc. That is why, at the same time, the innovations in the field of the immunomodulation are of a important interest: interleukine-2 (in particular IL-10, IL-15, IL-17 and IL-21) but also on interferons (in particular STING " stimulator of interferon genes "). The cellular immunotherapy emerges as a field of major interest, that it concerns lymphocytes reinjected with chimeric antigen receptor (CARs), or antibodies from tumoral cells. Finally, microbiota have also a significant interest because the immunogenic bacteria of the intestinal flora could become drug leads in oncology.
The 8th edition of the R&D Dating will cover, through selected presentations of top French experts, and face to face meeting, these aspects with the aim to facilitate and stimulate interactions between academic laboratories, networks of clinicians/biologists and industrial partners. The topics will include presentation of the predictive biomarkers of efficiency and side effect, the immunomodulatory and immunocellulary control points and therapeutic vaccines, rationalization of combinatorial therapeutic approaches, development and strengthening of preclinical models, new design of clinical trials with regard to the evolutions of standards of care, technological challenges in the control of the bioproduction related to advanced therapy medicinal products.
